September 25, 2025Open Access

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis reveals diverse survival outcomes in patients with BRCA-deficient tumors, highlighting genomic and immune factors.

BRCA2-deficient tumors with NF1 loss show improved survival rates compared to those without, indicating key genetic modifiers.
Patients with elevated HRD scores in BRCA1-deficient tumors tend to have significantly longer survival, emphasizing variation in outcomes.
Non-carriers of germline BRCA variants show diminished prognostic impact from residual disease post-surgery, contrasting with gBRCApv-carriers.
Evidence of immunosuppressive signaling and epithelial-mesenchymal transition is identified in short surviving BRCA1-deficient tumors.

Zwimpfer et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark